Traders Buy High Volume of Cerevel Therapeutics Call Options (NASDAQ:CERE)

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) was the recipient of some unusual options trading activity on Wednesday. Stock traders purchased 15,827 call options on the stock. This is an increase of approximately 633% compared to the average daily volume of 2,158 call options.

Insider Activity

In related news, Director N Anthony Coles sold 25,000 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $41.18, for a total value of $1,029,500.00. Following the sale, the director now owns 25,928 shares of the company’s stock, valued at $1,067,715.04. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Cerevel Therapeutics

A number of institutional investors have recently modified their holdings of the company. Entropy Technologies LP acquired a new position in Cerevel Therapeutics in the first quarter valued at $682,000. Versor Investments LP bought a new stake in Cerevel Therapeutics during the 4th quarter valued at $4,607,000. Calamos Advisors LLC acquired a new position in shares of Cerevel Therapeutics during the fourth quarter valued at about $12,945,000. Charles Schwab Investment Management Inc. increased its position in shares of Cerevel Therapeutics by 25.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 649,333 shares of the biotechnology company’s stock worth $27,532,000 after acquiring an additional 132,089 shares in the last quarter. Finally, Allianz Asset Management GmbH acquired a new stake in shares of Cerevel Therapeutics in the 4th quarter worth about $6,123,000. 87.73% of the stock is owned by institutional investors.

Cerevel Therapeutics Trading Up 0.8 %

Shares of NASDAQ CERE traded up $0.35 during trading on Wednesday, reaching $44.98. The company had a trading volume of 7,633,846 shares, compared to its average volume of 1,658,676. The stock has a market cap of $8.20 billion, a P/E ratio of -16.48 and a beta of 1.40. The company’s fifty day moving average price is $41.49 and its 200-day moving average price is $41.86. The company has a quick ratio of 10.22, a current ratio of 10.22 and a debt-to-equity ratio of 0.60. Cerevel Therapeutics has a 12 month low of $19.59 and a 12 month high of $44.99.

Cerevel Therapeutics (NASDAQ:CERE) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.12). As a group, research analysts expect that Cerevel Therapeutics will post -2.59 earnings per share for the current year.

About Cerevel Therapeutics

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.